Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
<Group xmlns="http://hl7.org/fhir">
<id value="179785"/>
<meta>
<versionId value="4"/>
<lastUpdated value="2023-12-04T20:30:06.799Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-definition"/>
</meta>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Group 179785</b></p><a name="179785"> </a><a name="hc179785"> </a><a name="179785-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 4; Last updated: 2023-12-04 20:30:06+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-comparator-definition.html">ComparatorDefinition</a></p></div><p><b>Artifact related artifact</b>: No display for RelatedArtifact (type: cite-as; citation: ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179785. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179785. Computable resource at: https://fevir.net/resources/Group/179785.)</p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>url</b>: <a href="https://fevir.net/resources/Group/179785">https://fevir.net/resources/Group/179785</a></p><p><b>identifier</b>: FEvIR Object Identifier/179785</p><p><b>name</b>: ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis</p><p><b>title</b>: ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>Description: usual-care pharmacologic thromboprophylaxis
Note: Thromboprophylaxis was provided at a dose and duration determined by the treating clinician according to local practice.
Note: Usual-care pharmacological thromboprophylaxis included both intermediate-intensity (in 27%) and prophylactic-intensity dosing (in 72%). Subgroup analyses may be informative to determine if there is a difference related to the intensity used in the control arm of the trial.</p>
</div><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>membership</b>: Conceptual</p><p><b>combinationMethod</b>: Any of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be more than half of the approved therapeutic dose for the treatment of venous thromboembolism.</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>ATTACC comparator arm</p>
</div><h3>Timings</h3><table class="grid"><tr><td style="display: none">-</td><td><b>ContextCode</b></td><td><b>Offset[x]</b></td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Start of trial</span></td><td>0-14</td><td>Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.</td></tr></table></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Any one of enoxaparin, dalteparin, tinzaparin, fondaparinux, or heparin according to local preference. Dose of agent specified to be consistent with guidelines for low dose thromboprophylaxis.</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>ACTIV-4a comparator arm</p>
</div><h3>Timings</h3><table class="grid"><tr><td style="display: none">-</td><td><b>ContextCode</b></td><td><b>Offset[x]</b></td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Start of trial</span></td><td>0-14</td><td>Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.</td></tr></table></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be sufficient to result in therapeutic anticoagulation.</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>REMAP-CAP comparator arm</p>
</div><h3>Timings</h3><table class="grid"><tr><td style="display: none">-</td><td><b>ContextCode</b></td><td><b>Offset[x]</b></td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Start of trial</span></td><td>0-14</td><td>Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.</td></tr></table></blockquote></div>
</text>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
<valueRelatedArtifact>
<type value="cite-as"/>
<citation
value="ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179785. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179785. Computable resource at: https://fevir.net/resources/Group/179785."/>
</valueRelatedArtifact>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
<valueContactDetail>
<name value="Brian S. Alper"/>
</valueContactDetail>
</extension>
<url value="https://fevir.net/resources/Group/179785"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net"/>
<value value="179785"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<name
value="ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis"/>
<title
value="ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis"/>
<status value="active"/>
<publisher value="Computable Publishing LLC"/>
<contact>
<telecom>
<system value="email"/>
<value value="support@computablepublishing.com"/>
</telecom>
</contact>
<description
value="Description: usual-care pharmacologic thromboprophylaxis
Note: Thromboprophylaxis was provided at a dose and duration determined by the treating clinician according to local practice.
Note: Usual-care pharmacological thromboprophylaxis included both intermediate-intensity (in 27%) and prophylactic-intensity dosing (in 72%). Subgroup analyses may be informative to determine if there is a difference related to the intensity used in the control arm of the trial."/>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<membership value="conceptual"/>
<combinationMethod value="any-of"/>
<characteristic>
<code>
<text value="Defined by CodeableConcept"/>
</code>
<valueCodeableConcept>
<text
value="Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be more than half of the approved therapeutic dose for the treatment of venous thromboembolism."/>
</valueCodeableConcept>
<exclude value="false"/>
<description value="ATTACC comparator arm"/>
<timing>
<contextCode>
<text value="Start of trial"/>
</contextCode>
<offsetRange>
<low>
<value value="0"/>
</low>
<high>
<value value="14"/>
<unit value="days"/>
<system value="http://unitsofmeasure.org"/>
<code value="d"/>
</high>
</offsetRange>
<text
value="Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician."/>
</timing>
</characteristic>
<characteristic>
<code>
<text value="Defined by CodeableConcept"/>
</code>
<valueCodeableConcept>
<text
value="Any one of enoxaparin, dalteparin, tinzaparin, fondaparinux, or heparin according to local preference. Dose of agent specified to be consistent with guidelines for low dose thromboprophylaxis."/>
</valueCodeableConcept>
<exclude value="false"/>
<description value="ACTIV-4a comparator arm"/>
<timing>
<contextCode>
<text value="Start of trial"/>
</contextCode>
<offsetRange>
<low>
<value value="0"/>
</low>
<high>
<value value="14"/>
<unit value="days"/>
<system value="http://unitsofmeasure.org"/>
<code value="d"/>
</high>
</offsetRange>
<text
value="Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician."/>
</timing>
</characteristic>
<characteristic>
<code>
<text value="Defined by CodeableConcept"/>
</code>
<valueCodeableConcept>
<text
value="Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be sufficient to result in therapeutic anticoagulation."/>
</valueCodeableConcept>
<exclude value="false"/>
<description value="REMAP-CAP comparator arm"/>
<timing>
<contextCode>
<text value="Start of trial"/>
</contextCode>
<offsetRange>
<low>
<value value="0"/>
</low>
<high>
<value value="14"/>
<unit value="days"/>
<system value="http://unitsofmeasure.org"/>
<code value="d"/>
</high>
</offsetRange>
<text
value="Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician."/>
</timing>
</characteristic>
</Group>
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-12-19
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change